EUVIMEDEUVIMED entdecken
Crossref

N6-methyadenosine modified SUV39H2 regulates homologous recombination through epigenetic repression of DUSP6 in gastric cancer

Jing Yang, Penghui Xu, Zetian Chen, Xing Zhang, Yiwen Xia, Lang Fang, Li Xie, Bowen Li, Zekuan Xu

Cancer Letters · 2023

DOI: 10.1016/j.canlet.2023.216092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2023. Verfasst von Jing Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu Province, China. Hauptthemen laut MEDLINE: Stomach Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite many advances in treatment over the past few years, the poor 5-year survival rate and high recurrence rate of gastric cancer (GC) remain unsatisfactory. As the most abundant epigenetic modification in the eukaryotic mRNA, N6-methyladenosine (m6A) methylation participates in tumor progression and tissue development. During tumor progression, DNA damage repair mechanisms can be reprogrammed to give new growth advantages on tumor clones whose genomic integrity is disturbed. Here we detected the elevated SUV39H2 expression in GC tissues and cell lines. Functionally, SUV39H2 promoted GC proliferation and inhibited apoptosis in vitro and in vivo. Mechanistically, METTL3-mediated m6A modification promotes mRNA stability of SUV39H2 in an IGF2BP2 dependent manner, resulting in upregulated mRNA expression of SUV39H2. As a histone methyltransferase, SUV39H2 was verified to increase the phosphorylation level of ATM through transcriptional repression of DUSP6, thereby promoting HRR and ultimately inhibiting GC chemosensitivity to cisplatin. Collectively, these results indicate the specific mechanism of m6A-modified SUV39H2 as a histone methyltransferase promoting HRR to inhibit the chemosensitivity of GC. SUV39H2 is expected to become a key target in the precision targeted therapy of GC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsHumansEpigenetic RepressionCell Line, TumorHomologous RecombinationHistone MethyltransferasesRNA, MessengerMethyltransferasesRNA-Binding ProteinsDual Specificity Phosphatase 6Histone-Lysine N-Methyltransferase

Stichwörter der Autor:innen

DSBsGastric cancerHomologous recombinationSUV39H2m(6)A modification

Substanzen

Histone MethyltransferasesRNA, MessengerMETTL3 protein, humanMethyltransferasesIGF2BP2 protein, humanRNA-Binding ProteinsDUSP6 protein, humanDual Specificity Phosphatase 6SUV39H2 protein, humanHistone-Lysine N-Methyltransferase

Autor:innen und Institutionen

  • Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu Province, China.
  • Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu Province, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical Uni…

Zitieren

APA

Yang, J., Xu, P., Chen, Z., Zhang, X., Xia, Y., Fang, L., Xie, L., Li, B., & Xu, Z. (2023). N6-methyadenosine modified SUV39H2 regulates homologous recombination through epigenetic repression of DUSP6 in gastric cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2023.216092

Vancouver

Yang J, Xu P, Chen Z, Zhang X, Xia Y, Fang L, et al. N6-methyadenosine modified SUV39H2 regulates homologous recombination through epigenetic repression of DUSP6 in gastric cancer. Cancer Letters. 2023. doi:10.1016/j.canlet.2023.216092

BibTeX
@article{Yang2023,
  author = {Yang, Jing and Xu, Penghui and Chen, Zetian and Zhang, Xing and Xia, Yiwen and Fang, Lang and Xie, Li and Li, Bowen and Xu, Zekuan},
  title = {N6-methyadenosine modified SUV39H2 regulates homologous recombination through epigenetic repression of DUSP6 in gastric cancer},
  journal = {Cancer Letters},
  year = {2023},
  doi = {10.1016/j.canlet.2023.216092}
}
Kostenlos starten →